Cargando…

Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs

Different attempts have been made in the past two decades to develop radiolabeled peptide conjugates with enhanced pharmacokinetic properties in order to improve the application for tumor imaging and peptide receptor radionuclide therapy (PRRT), which targets the cholecystokinin-2 receptor (CCK2R)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zavvar, Taraneh Sadat, Hörmann, Anton Amadeus, Klingler, Maximilian, Summer, Dominik, Rangger, Christine, Desrues, Laurence, Castel, Hélène, Gandolfo, Pierrick, von Guggenberg, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959130/ https://www.ncbi.nlm.nih.gov/pubmed/37052226 http://dx.doi.org/10.3390/ph16020278

Ejemplares similares

Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements via the Inclusion of Proline into the Peptide Sequence
por: Klingler, Maximilian, et al.
Publicado: (2020)

Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m
por: Klingler, Maximilian, et al.
Publicado: (2019)

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting
por: Klingler, Maximilian, et al.
Publicado: (2018)

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum
por: Klingler, Maximilian, et al.
Publicado: (2019)

Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13
por: Klingler, Maximilian, et al.
Publicado: (2019)

Exploiting the Concept of Multivalency with (68)Ga- and (89)Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression
por: Summer, Dominik, et al.
Publicado: (2018)

Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression
por: Summer, Dominik, et al.
Publicado: (2018)

Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue
por: Pfister, Joachim, et al.
Publicado: (2015)

Effect of N-Terminal Peptide Modifications on In Vitro and In Vivo Properties of (177)Lu-Labeled Peptide Analogs Targeting CCK2R
por: Hörmann, Anton Amadeus, et al.
Publicado: (2023)

Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177
por: Hörmann, Anton Amadeus, et al.
Publicado: (2020)

Automated Synthesis of (68)Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting
por: Hörmann, Anton Amadeus, et al.
Publicado: (2022)

Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs
por: Holzleitner, Nadine, et al.
Publicado: (2023)

The core autophagy protein ATG9A controls dynamics of cell protrusions and directed migration
por: Campisi, Daniele, et al.
Publicado: (2022)

The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features
por: Castel, Hélène, et al.
Publicado: (2017)

Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
por: Hörmann, Anton A., et al.
Publicado: (2021)

Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin (177)Lu-PP-F11N
por: Grob, Nathalie M., et al.
Publicado: (2021)

Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding
por: Summer, Dominik, et al.
Publicado: (2017)

Down-Regulation of GABA(A) Receptor via Promiscuity with the Vasoactive Peptide Urotensin II Receptor. Potential Involvement in Astrocyte Plasticity
por: Desrues, Laurence, et al.
Publicado: (2012)

Development of Novel (111)-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours
por: Poret, Benjamin, et al.
Publicado: (2020)

The Autophagy Machinery: A New Player in Chemotactic Cell Migration
por: Coly, Pierre-Michaël, et al.
Publicado: (2017)

From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial
por: Pawlak, Dariusz, et al.
Publicado: (2016)

Hybrid Imaging Agents for Pretargeting Applications Based on Fusarinine C—Proof of Concept
por: Summer, Dominik, et al.
Publicado: (2020)

Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor
por: Lipiński, Piotr F. J., et al.
Publicado: (2018)

Oxidant and Antioxidant Effects of Gentisic Acid in a (177)Lu-Labelled  Methionine-Containing Minigastrin Analogue
por: Trindade, Victoria, et al.
Publicado: (2020)

Signaling Network Response to α-Particle–Targeted Therapy with the (225)Ac-Labeled Minigastrin Analog (225)Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors
por: Qin, Yun, et al.
Publicado: (2023)

Targeting the Urotensin II/UT G Protein-Coupled Receptor to Counteract Angiogenesis and Mesenchymal Hypoxia/Necrosis in Glioblastoma
por: Le Joncour, Vadim, et al.
Publicado: (2021)

Development of the First (18)F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety
por: Günther, Thomas, et al.
Publicado: (2023)

Fusarinine C, a novel siderophore‐based bifunctional chelator for radiolabeling with Gallium‐68
por: Zhai, Chuangyan, et al.
Publicado: (2015)

Evaluation of the Impact of the Cancer Therapy Everolimus on the Central Nervous System in Mice
por: Dubois, Martine, et al.
Publicado: (2014)

The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice
por: Nicola, Celeste, et al.
Publicado: (2021)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020)

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [(177)Lu]Lu-PP-F11N
por: Grzmil, Michal, et al.
Publicado: (2021)

Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [(177)Lu]Lu-PP-F11N
por: Grzmil, Michal, et al.
Publicado: (2020)

Side‐On Bonded Beryllium Dinitrogen Complexes
por: Deng, Guohai, et al.
Publicado: (2020)

Pretargeted Imaging with Gallium-68—Improving the Binding Capability by Increasing the Number of Tetrazine Motifs
por: Summer, Dominik, et al.
Publicado: (2018)

Increased plasma levels of endozepines, endogenous ligands of benzodiazepine receptors, during systemic inflammation: a prospective observational study
por: Clavier, Thomas, et al.
Publicado: (2014)

Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles
por: Rangger, Christine, et al.
Publicado: (2013)

Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles
por: Rangger, Christine, et al.
Publicado: (2012)

Novel Bifunctional Cyclic Chelator for (89)Zr Labeling–Radiolabeling and Targeting Properties of RGD Conjugates
por: Zhai, Chuangyan, et al.
Publicado: (2015)

Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD—In Vivo Imaging Studies in Human Xenograft Tumors
por: Zhai, Chuangyan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rb27jokmlevnd9qdhn969rsf9i